Clinical Trials Logo
  1. Home
  2. Hospital-Acquired Pneumonia
  3. NCT04774094

Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)

Hospital-Acquired Pneumonia Clinical Trial

Official title:
A SINGLE ARM, OPEN-LABEL, MULTI-CENTER, INTERVENTIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHINESE ADULTS WITH HAP (INCLUDING VAP)

Clinical Trial Summary

This is a prospective, single arm, open-label, multi-center clinical study evaluating the effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have initiated treatment with CAZ-AVI in an inpatient hospital setting. The duration of antibiotic treatment with the CAZ-AVI is 7-14 days. Participants must receive intravenously (IV) CAZ-AVI in the hospital for at least 7 full days. There are no formal hypothesis tests planned for this study. The number and percent of participants having clinical cure, failure, and indeterminate at TOC visit in the cMITT analysis population will be summarized.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04774094
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 4
Start date May 21, 2021
Completion date May 4, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT01266863 - E Test Strips Applied to Bronchoalveolar Lavage for Suspicion of Hospital-acquired Pneumonia to Accelerate Antibiogram Analysis. N/A
Not yet recruiting NCT06168734 - Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP Phase 3
Not yet recruiting NCT01940731 - Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults Phase 2
Not yet recruiting NCT06028217 - Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
Completed NCT01561469 - Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin N/A
Terminated NCT00543608 - Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Phase 2
Enrolling by invitation NCT04055922 - Comparison of Solid Organ Transplant
Completed NCT04403971 - 0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia N/A
Completed NCT05060718 - HOspital NEtwork STudy - Preparation for a Randomized Evaluation of Anti-Pneumonia Strategies
Active, not recruiting NCT05785442 - Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia Phase 2
Completed NCT04700202 - Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit
Not yet recruiting NCT05418517 - Hospital Acquired Pneumonia in Temporary Tracheostomy
Recruiting NCT04381247 - Comprehensive Molecular Diagnosis and Management of Hospital- and Ventilator-associated Pneumonia in Norway
Recruiting NCT05483309 - Feasibility Study of Contemporary Diagnostics for Patients With Suspected Hospital-Acquired Pneumonia. N/A
Completed NCT04937075 - Impact of Antimicrobial Stewardship on Outcomes of Patients With Hospital-acquired Pneumonia Due to Gram-negative Bacilli - A Before-after Study
Completed NCT03496220 - Effect of Angulus on Patient-elevation Compliance N/A
Not yet recruiting NCT05914584 - "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype. Phase 2/Phase 3
Completed NCT05663905 - Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients Phase 4
Terminated NCT03361085 - Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP) N/A
Completed NCT05624684 - Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.